Swiss drugmaker Roche on Tuesday named a new head of its $13-billion-per-year diagnostics business and also said board member Peter Voser is stepping down to focus on his expanded duties as interim head of Swiss engineering group ABB.
Roche’s new diagnostics boss, Thomas Schinecker, fills a post that had been led for months on an interim basis by Michael Heuer, who is retiring. Roche’s diagnostics unit includes diabetes care, sophisticated laboratory equipment and tests aimed at personalizing cancer treatment.
With Schinecker, 44, Roche has looked inside the company to finally fill a key leadership position vacated last August by Roland Diggelmann. Schinecker began his career in 2003 as a trainee for Roche Diagnostics before moving up the ranks in jobs in the United States, Singapore, Austria, Sweden and Switzerland.
“Thomas Schinecker has broad and international experience in our business,” Roche CEO Severin Schwan said in a statement.
Roche’s head of group communications, Stephan Feldhaus, is also leaving in September, to be replaced by Barbara Schaedler, who is now head of public affairs at E.ON SE.
Voser had been on Roche’s board since 2011 but wants to dedicate more time as interim CEO of ABB, a post he has filled since Ulrich Spiesshofer left the robotics and automation company in April.
By John Miller
Source: Reuters
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
